AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What's New in Clinical Trials for Bullous Pemphigoid?

Description

The presentation discusses advancements in clinical trials and treatment for Bullous Pemphigoid (BP), a blistering skin disease predominantly affecting the elderly. The speaker, with extensive experience in the field, emphasizes the importance of early recognition of the disease, which often presents as severe itching before blisters appear. The mortality rate remains significant, indicating the need for better management strategies. The presentation outlines the development and validation of the Bullous Pemphigoid Disease Area Index (BPDAI) to assess disease severity and treatment efficacy. A focus is on the elderly patient demographic, known for handling comorbidities and the complications associated with common steroid treatments. Current standard treatments include topical and systemic corticosteroids, though new immunotherapeutics such as Dupilumab show promise in recent trials. The results from ongoing studies indicate that Dupilumab may effectively manage BP, particularly in the maintenance phase, addressing underlying pathophysiology without the adverse effects associated with traditional treatments. The speaker urges further education on BP symptoms and treatment advancements to aid both patients and healthcare providers.

View more

Conclusions

  • Bullous pemphigoid (BP) often presents first with pruritus and non-bullous rash before evolving into blisters.
  • Early recognition of BP is crucial for effective disease management, as advanced stages are harder to control.
  • A comprehensive treatment approach includes both initial and control therapies to avoid long-term corticosteroid use.
  • The Bullous Pemphigoid Disease Area Index (BPDAI) is validated for assessing disease activity and response to treatment.
  • Patients' quality of life significantly deteriorates due to BP and remains a concern even when the disease is controlled.
  • Elderly patients with BP may experience complications from treatments due to comorbidities and require careful management.
  • Targeted therapies, like dupilumab, have shown promise in enhancing the treatment landscape for BP.
  • Topical corticosteroids are often preferred over systemic corticosteroids due to better safety profiles and efficacy.
  • Immunosuppressive agents, such as rituximab, may be necessary for more severe cases but should be used with caution.
  • The role of immune pathways, especially type 2 immune responses, is critical in understanding the pathophysiology of BP.
  • Borradori, L., Murrell, D. F., & Hall, R. (2015). Textbook of Blistering Diseases. Springer.
  • Murrell, D. F., Daniel, B. S., Joly, P., Borradori, L. ... Werth, V. P. (2013). Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. JAAD, doi:10.1016/j.jaad.2011.06.032
  • Patsatsi, A. (2012). Clin Dev Immunol.
  • Lévy-Sitbon, C. (2014). Dermatology.
  • Wijayante, A. (2016). Acta Derm Venereol.
  • TABQOL: Tjokrowidjaja, A. et al. (2013). Br J Dermatol, 169(5), 1000-6.
  • ABQOL: Sebaratnam, D. et al. (2013). JAMA Dermatol, 149(10), 1186-91.
  • Joly, P. et al. (2002). A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid. N Engl J Med, 346, 321-327.
  • Amagai, M. et al. (2017). J Dermatol Sci, 85, 77-84.
  • Zhao, L. et al. (2023). JAMA Dermatol, 159, 953-960.